Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary Rock Creek Pharmaceuticals Inc., announced today that the Alzheimer's study of the company's dietary supplement Anatabloc® has screened and enrolled its first patient.
The Alzheimer's study, entitled, "A Three Month, Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability and Potential Effect of the Dietary Supplement Anatabine in Subjects with Alzheimer's Disease," has its origins in basic research conducted at the Roskamp Institute (Sarasota, FL) and from case reports of beneficial effects of the company's dietary supplement Anatabloc® in individuals using the nutritional supplement under their physician's care.
The anatabine citrate used in Anatabloc® has been shown to be effective in lowering amyloid levels and other markers of inflammation in both tissue studies conducted in a laboratory setting and in animal research. In addition, Anatabloc® has been reported by others to be a useful nutritional supplement in Alzheimer's disease. The company received a patent for the synthesis of anatabine in June 2012, and a patent is pending for the Anatabloc® formulation. Preparations for the Alzheimer's study were extensive and included pharmacokinetic and tolerability studies, a review of the
- Get Livefyre
- FAQ
